Globe Life
GL
$164.17
-1.15%
Globe Life Inc. is an insurance holding company that provides life insurance, supplemental health insurance, and annuities to a broad base of customers, operating through three reportable segments: life insurance, supplemental health insurance, and investments. The company is a well-established, niche-focused insurer that distributes primarily through direct-to-consumer and worksite marketing channels, distinguishing itself from large-cap diversified carriers with a lean, high-margin operating model. The current investor narrative centers on Globe Life's ability to sustain mid-single-digit premium growth while navigating a relatively soft life insurance demand environment and persistent regulatory scrutiny of supplemental health products. Recent attention has focused on the company's capital return program, including consistent share repurchases and a modest dividend, alongside questions about whether its premium valuation relative to peers is justified by its superior return on equity and conservative balance sheet.…
GL
Globe Life
$164.17
Investment Opinion: Should I buy GL Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness. The core thesis is that Globe Life is a high-quality, conservatively managed insurer trading at a deep discount to peers and its own history, but near-term momentum and decelerating growth warrant patience. The analyst consensus of Buy with an average target of $192.91 (17.5% upside) supports a constructive view, but the wide target range ($166–$225) and recent 3-month underperformance of 11.48% versus SPY suggest that conviction is not yet justified for an aggressive Buy.
The supporting evidence for a Hold is balanced: the trailing PE of 9.78x is below the industry average of 12x–15x and the stock's historical range, while the PB of 1.89x is below the peer average of ~2.5x. Return on equity of 19.43% is well above the industry average, and free cash flow of $1.23 billion TTM comfortably covers the $21.4 million quarterly dividend and $240.5 million in buybacks. However, revenue growth of 5.35% is modest, and the forward PE of 9.95x being higher than the trailing PE implies flat earnings expectations. The PEG ratio of 0.51 is attractive but less meaningful given the low growth rate, and the dividend yield of 0.76% is modest.
The biggest risks that could invalidate the Hold thesis are a breakdown below the $150 support level, which would signal a deeper trend reversal, and any adverse regulatory development in supplemental health that pressures the health segment's $416.9 million quarterly revenue. Additionally, if Q2 2026 earnings show net margin falling below 17% or revenue growth decelerating below 4%, the stock could test the 52-week low of $127.85. This Hold would upgrade to Buy if the stock stabilizes above $160 and forward EPS estimates are revised upward, or if the PE compresses below 9x while ROE remains above 19%. It would downgrade to Sell if revenue growth turns negative or if the company cuts its dividend or suspends buybacks. Relative to its history and peers, GL appears undervalued, but the market is demanding evidence of sustainable growth before re-rating the multiple.
Sign up to view all
GL 12-Month Price Forecast
Globe Life presents a classic value-versus-momentum dilemma: the stock is statistically cheap on every metric (PE, PB, PEG) and offers a 17.5% upside to analyst targets, but it is in a clear near-term downtrend with decelerating revenue growth. The low beta of 0.439 and high ROE of 19.43% make it a quality defensive holding, yet the market is demanding evidence that growth can reaccelerate before re-rating the multiple. I would upgrade to bullish if Q2 2026 earnings show revenue growth above 6% and net margin above 19%, or if the stock breaks above $180 on strong volume. I would downgrade to bearish if revenue growth falls below 4%, net margin drops below 17%, or the stock breaks below $150, which would likely trigger further analyst downgrades and a test of the 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globe Life's 12-month outlook, with a consensus price target around $192.91 and implied upside of +17.5% versus the current price.
Average Target
$192.91
0 analysts
Implied Upside
+17.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$166 - $225
Analyst target range
Eleven analysts cover Globe Life, with a consensus recommendation of Buy and an average target price of $192.91. This implies an upside of approximately 17.5% from the current price of $164.17. The recommendation mean of 1.91 (on a scale where 1 is Strong Buy and 5 is Strong Sell) confirms a bullish tilt, with no sell ratings among the covering firms. Recent institutional ratings show a mix of Overweight, Outperform, and Hold actions, with no downgrades in the past three months, indicating stable sentiment. The target price range spans from a low of $166.00 to a high of $225.00, a spread of $59.00 or roughly 36% of the current price. The low target of $166.00 implies just 1.1% upside, essentially pricing in flat performance and likely reflecting concerns about margin compression or slower growth. The high target of $225.00 assumes a 37% upside and would require multiple expansion or accelerating earnings growth, potentially driven by new product launches or favorable regulatory outcomes. The wide spread signals high uncertainty among analysts, which is consistent with the stock's recent underperformance and the divergent views on the life insurance sector's outlook. The consensus EPS estimate of $19.50 for the current year, with a range of $19.17 to $19.81, suggests modest earnings growth, and the estimated revenue average of $7.47 billion implies low single-digit top-line expansion. Overall, the analyst community leans bullish, but the wide target range and recent price weakness suggest that conviction is not uniform.
Bulls vs Bears: GL Investment Factors
The bear case currently has stronger near-term evidence due to GL's sharp 3-month underperformance (-8.35% vs. SPY +3.13%) and decelerating revenue growth of 5.35%, which suggests the market is repricing the stock lower despite its cheap valuation. However, the bull case rests on a compelling valuation floor: a 9.78x PE, 1.89x PB, and 19.43% ROE that are all superior to or below peer averages, plus a 17.5% analyst target upside. The single most important tension is whether the recent price weakness is a temporary pullback within a longer-term uptrend or the start of a deeper de-rating driven by structural growth concerns. If GL can stabilize around $160 and show even modest margin expansion, the value case likely prevails; a breakdown below $150 would validate the bear thesis and likely trigger further analyst downgrades.
Bullish
- Deep Value Multiple vs. History and Peers: GL trades at a trailing PE of 9.78x and forward PE of 9.95x, well below the life insurance sector average of 12x–15x and the stock's own historical range of 7.3x–15.2x. The PB ratio of 1.89x is also below the industry average of ~2.5x and its five-year average of ~2.2x, suggesting the market is pricing in excessive pessimism.
- High ROE and Conservative Balance Sheet: Return on equity is 19.43%, materially above the industry average, while debt-to-equity is only 0.44 and the current ratio is a robust 9.66. Interest coverage of 10.83x confirms the company can comfortably service its obligations, and free cash flow of $1.23 billion TTM provides ample liquidity for shareholder returns.
- Strong Analyst Consensus with 17.5% Upside: Eleven analysts rate GL a Buy with an average target of $192.91, implying 17.5% upside from the current $164.17. The recommendation mean of 1.91 (1=Strong Buy) and zero sell ratings indicate broad institutional confidence, and the high target of $225 suggests meaningful optionality if growth reaccelerates.
- Consistent Capital Return and Low Payout Risk: GL repurchased $240.5 million of stock in Q1 2026 alone and paid $21.4 million in dividends, with a payout ratio of just 7.41%. This leaves substantial capacity for continued buybacks and dividend increases, which should support EPS growth even with modest revenue expansion.
Bearish
- Decelerating Revenue Growth: Q1 2026 revenue grew only 5.35% year-over-year to $1.56 billion, continuing a trend of mid-single-digit expansion that is below the broader market's growth rate. This slow top-line trajectory limits operating leverage and makes it difficult to justify multiple expansion without margin improvement.
- Recent Severe Underperformance: GL has declined 8.35% over the past three months and 3.33% over the past month, underperforming the S&P 500 by 11.48% and 5.45% respectively. This sharp divergence from the longer-term uptrend suggests deteriorating near-term momentum and potential trend reversal.
- Wide Analyst Target Dispersion: The analyst target range spans from $166 to $225, a spread of $59 or 36% of the current price, indicating high uncertainty about the company's outlook. The low target implies only 1.1% upside, reflecting concerns about margin compression or regulatory headwinds in supplemental health.
- Flat Forward Earnings Expectations: The forward PE of 9.95x is slightly above the trailing PE of 9.78x, implying analysts expect flat to slightly declining earnings growth. The consensus EPS estimate of $19.50 for the current year represents minimal growth, and the PEG ratio of 0.51, while low, is less meaningful given the slow growth rate.
GL Technical Analysis
Globe Life is in a sustained uptrend over the trailing twelve months, with a 1-year price change of +20.32% versus the S&P 500's +16.00%, delivering relative strength of +4.32%. The current price of $164.17 sits at approximately 57% of the 52-week range (low of $127.85, high of $191.55), meaning the stock is in the upper half of its annual range but well off its peak. This positioning suggests a stock that has been a solid performer but is not overextended near highs, leaving room for either a breakout or a deeper pullback depending on near-term momentum. Recent momentum has turned negative, with a 1-month decline of -3.33% and a 3-month decline of -8.35%, diverging sharply from the positive 1-year trend. The 1-month relative strength versus SPY is -5.45%, and the 3-month relative strength is -11.48%, indicating significant underperformance over the past quarter. This divergence could signal a trend reversal or a temporary pullback within a longer-term uptrend, especially given the 6-month change of +12.57% and YTD change of +18.60%, which remain positive. The stock's beta of 0.439 is notably low, meaning it is roughly 56% less volatile than the broader market, which may appeal to risk-averse investors but also limits upside participation in strong rallies. Key technical support lies near the 52-week low of $127.85, while resistance is at the 52-week high of $191.55. A breakdown below the recent consolidation zone around $160 could accelerate selling toward the $150 area, while a breakout above $180 would signal renewed momentum and a potential retest of the highs. The maximum drawdown of -12.15% over the period reflects moderate risk, and the low beta suggests position sizing can be larger relative to high-beta names for equivalent portfolio risk.
Beta
0.44
0.44x market volatility
Max Drawdown
-12.2%
Largest decline past year
52-Week Range
$128-$192
Price range past year
Annual Return
+20.3%
Cumulative gain past year
| Period | GL Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | +1.9% |
| 3m | -8.4% | +3.9% |
| 6m | +12.6% | +12.1% |
| 1y | +20.3% | +19.2% |
| ytd | +18.6% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GL Fundamental Analysis
Globe Life's revenue trajectory remains positive but is decelerating, with Q1 2026 revenue of $1.56 billion representing 5.35% year-over-year growth. This compares to Q4 2025 revenue of $1.52 billion and Q1 2025 revenue of $1.48 billion, showing a steady but modest upward trend. The life segment is the larger contributor at $853.2 million, while the health segment adds $416.9 million, together driving the top line. The growth rate in the mid-single digits is consistent with a mature insurance business, and the investment case hinges on margin expansion and capital return rather than rapid revenue acceleration. Profitability is robust, with Q1 2026 net income of $270.5 million and a net margin of 17.35%, while the gross margin stands at 49.37% for the quarter. The operating margin is 23.60%, and the EBITDA ratio is 23.60%, reflecting consistent core profitability. Over the past four quarters, net income has ranged from $252.7 million to $387.8 million, with the Q3 2025 spike partly due to lower expenses. Margins have been relatively stable, with net margin hovering between 17% and 25%, and the company consistently generates positive earnings, which is typical for a well-run life insurer. The balance sheet is conservatively managed, with a debt-to-equity ratio of 0.439 and a current ratio of 9.66, indicating ample liquidity. Free cash flow for Q1 2026 was $396.0 million, and trailing twelve-month free cash flow is $1.23 billion, providing strong internal funding for dividends and buybacks. The company repurchased $240.5 million of stock in Q1 2026 and paid $21.4 million in dividends, demonstrating a commitment to shareholder returns. Return on equity is 19.43%, well above the industry average, and the interest coverage ratio of 10.83 times reflects a comfortable ability to service debt. Overall, the financial health is strong, with no reliance on external financing for growth.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+5.3%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GL Overvalued?
Because Globe Life is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 9.78x, while the forward PE is 9.95x, a slight premium to the trailing multiple. This narrow gap suggests the market is not pricing in significant earnings growth over the next year, which aligns with the modest 5.35% revenue growth and stable margins. The forward PE being marginally higher than trailing implies that analysts expect earnings to remain relatively flat or decline slightly, which is consistent with the low estimated EPS growth. Compared to the insurance-life industry, Globe Life's PE of 9.78x is below the sector average, which typically ranges from 12x to 15x for established life insurers. The PS ratio of 1.89x and PB ratio of 1.89x also appear reasonable, with the PB ratio below the industry average of around 2.5x. The PEG ratio of 0.51 is particularly attractive, suggesting the stock is undervalued relative to its earnings growth rate, though the low growth rate itself limits the significance. The dividend yield of 0.76% is modest but sustainable, with a payout ratio of only 7.41%, leaving ample room for future increases or buybacks. Historically, Globe Life's PE ratio has ranged from a low of 7.3x in mid-2024 to a high of 15.2x in early 2022, with the current 9.78x sitting in the lower half of that range. The PS ratio of 1.89x is near the low end of its historical band, which has ranged from 5.4x to 9.7x over the past five years, though the current PS is distorted by the recent decline in market cap. The PB ratio of 1.89x is also below the historical average of around 2.2x, suggesting the stock is trading at a discount to its own history. This could represent a value opportunity if fundamentals remain intact, but it also reflects the market's concerns about growth and regulatory risks.
PE
9.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Globe Life's financial risks are moderate but centered on its reliance on consistent underwriting margins and investment income. The company carries $34 million in quarterly interest expense with a debt-to-equity ratio of 0.44, which is manageable but not trivial for an insurer. More importantly, net margin has fluctuated between 17.0% and 25.6% over the past four quarters, with Q3 2025 spiking to 25.6% partly due to lower expenses, indicating earnings volatility that could surprise investors. Revenue concentration in the life segment ($853.2 million) and health segment ($416.9 million) means any adverse claims experience or pricing pressure in these core lines would directly hit profitability. Additionally, the company's growth depends on sustaining mid-single-digit premium increases in a soft life insurance demand environment, and any acceleration in policy lapses could undermine the capital return program that investors have come to rely on.
Market and competitive risks are elevated given GL's recent underperformance and premium valuation relative to its own history. The stock trades at a forward PE of 9.95x, which is below the sector average but above its own mid-2024 low of 7.3x, leaving room for further multiple compression if growth disappoints. The beta of 0.439 means GL is less sensitive to broad market swings, but this also limits upside participation in rallies, and the stock has underperformed SPY by 11.48% over three months. Competitive disruption from larger, diversified carriers with greater scale and digital capabilities could pressure Globe Life's niche direct-to-consumer and worksite channels. Regulatory scrutiny of supplemental health products remains a persistent overhang, and any adverse ruling could force product redesigns, increase compliance costs, or reduce sales, directly impacting the health segment's $416.9 million quarterly revenue.
The worst-case scenario for GL would involve a combination of regulatory action against supplemental health products, a spike in claims severity, and a broader de-rating of life insurance stocks. In this scenario, the stock could retest its 52-week low of $127.85, representing a decline of approximately 22% from the current price of $164.17. If analyst bear-case targets are revised downward in response, the low target of $166 could be abandoned, and the stock could trade toward its historical low PE of 7.3x, implying a price near $142 based on current EPS. A more severe outcome, such as a dividend cut or a halt in buybacks due to capital strain, could push the stock below $130, resulting in a loss of 20% or more from current levels. Given the maximum drawdown of -12.15% over the past year, a 20%+ drawdown would be a significant deviation from recent history but is plausible if multiple negative catalysts converge.
FAQ
The most severe risk is regulatory scrutiny of supplemental health products, which could reduce revenue in the health segment ($416.9 million quarterly) and increase compliance costs. Second, earnings volatility is a concern, with net margin fluctuating between 17.0% and 25.6% over the past four quarters, and any compression below 17% could trigger a de-rating. Third, competitive pressure from larger, diversified insurers with greater digital capabilities could erode Globe Life's niche direct-to-consumer and worksite channels. Fourth, macro sensitivity is low given the 0.439 beta, but a rotation away from defensive stocks could reduce demand for GL. Ranked by severity: regulatory, earnings volatility, competitive, and macro.
The 12-month forecast has three scenarios: a base case (55% probability) with a target range of $175–$193, assuming revenue growth of 4–6% and stable margins; a bull case (25% probability) targeting $192–$225, driven by margin expansion and multiple re-rating; and a bear case (20% probability) targeting $128–$150, triggered by regulatory headwinds or margin compression. The base case is most likely, hinging on the assumption that Globe Life maintains its current growth trajectory and capital return program without major negative surprises. The analyst average target of $192.91 aligns with the upper end of the base case, implying 17.5% upside if the company meets expectations.
GL appears undervalued on both absolute and relative bases. The trailing PE of 9.78x is below the life insurance sector average of 12x–15x and sits in the lower half of its own historical range of 7.3x–15.2x. The PB ratio of 1.89x is below the industry average of ~2.5x and the stock's five-year average of ~2.2x, while the PEG ratio of 0.51 suggests the stock is cheap relative to its earnings growth rate. However, the forward PE of 9.95x being slightly above the trailing PE implies the market expects flat earnings, which limits the case for immediate multiple expansion. The market is pricing in concerns about slow growth and regulatory risks, so the stock is undervalued only if those fears prove overblown.
GL is a good buy for value-oriented investors with a medium-term horizon, given its trailing PE of 9.78x, PB of 1.89x, and 17.5% upside to the analyst average target of $192.91. The company's 19.43% ROE and $1.23 billion in trailing free cash flow support a sustainable dividend and buyback program, providing a margin of safety. However, the stock has fallen 8.35% over three months and underperformed the S&P 500 by 11.48%, indicating negative momentum that could persist. The biggest downside risk is a retest of the 52-week low of $127.85, representing a 22% decline, if revenue growth decelerates further or regulatory headwinds intensify. Therefore, it is a good buy for patient investors who can tolerate near-term volatility, but not for those seeking immediate capital appreciation.
GL is better suited for long-term investment (minimum 2–3 years) rather than short-term trading. The stock's low beta of 0.439 and modest dividend yield of 0.76% mean it lacks the volatility that short-term traders seek, while its consistent buybacks and 19.43% ROE support gradual compounding over time. The recent 3-month decline of 8.35% and negative momentum suggest that near-term upside is limited, and a value re-rating may take several quarters to materialize. Long-term investors can benefit from the discounted valuation and capital return program, but should be prepared for periods of underperformance relative to the broader market. A minimum holding period of 2–3 years allows time for regulatory clarity and potential growth acceleration.